Memory Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Loss of the neuronal kinase DCLK3 leads to anxiety-like behaviour and memory deficits.
The Role of Astrocytes in Synaptic Dysfunction and Memory Deficits in Alzheimer's Disease.
Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier.
Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026Compensation Training and Lifestyle Modifications to Promote Healthy Aging in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention (Brain Boosters 2)
- Q4 2026Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal Lobe
- Q4 2030Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
Clinical MilestonesViewHide
- 2026-07-07Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension StudyResults expected Q4 2030
- 2025-10-08Compensation Training and Lifestyle Modifications to Promote Healthy Aging in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention (Brain Boosters 2)Results expected Q3 2026
- 2025-10-03Behavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal LobeResults expected Q4 2026
- 2026-07-07ClinicalInvestigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension StudyResults expected Q4 2030
- 2025-10-08ClinicalCompensation Training and Lifestyle Modifications to Promote Healthy Aging in Persons at Risk for Alzheimer's Disease: a Digital Application Supported Intervention (Brain Boosters 2)Results expected Q3 2026
- 2025-10-03ClinicalBehavioral and Pharmacological Manipulation of Time Cell Activity in the Human Mesial Temporal LobeResults expected Q4 2026
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Alzheimer Disease10
- Memory Disorders4
- Hippocampus3
- Neurodegenerative Diseases3
- Synapses3
- Amyloidosis2
- Astrocytes2
- Mice, Transgenic2
Leading journals6
- Biomolecules2
- Brain : a journal of neurology2
- Scientific reports2
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- Ageing research reviews1
- Annals of neurology1
Leading researchers8
- Bemelmans AP2
- Dolga AM2
- Eisel ULM2
- Abebe D1
- Agostinho P1
- Agostini MA1
- Akter M1
- Alexopoulos AV1
Affiliations (unnormalised)6
- Groningen Institute for Evolutionary Life Sciences2
- Université Paris-Saclay2
- Applied Research Center1
- Auburn University1
- Beijing Key Laboratory of Aging and Geriatrics1
- Beijing Key Laboratory of Sports Function Assessment and Technical Analysis1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Memory disorders are disturbances in the registration, retention, or recall of impressions. The grounding links memory impairment with several conditions, including dementia, craniocerebral trauma, encephalitis, alcoholism, schizophrenia, and other disorders.
The supplied material supports memory disorders as being associated with underlying conditions rather than a single cause. These include dementia, craniocerebral trauma, encephalitis, alcoholism, schizophrenia, and stress-related states that can impair memory function.
The literature grounding points to disrupted hippocampal function, altered synaptic plasticity, and impaired learning-related processes as key biological correlates of memory impairment. In Alzheimer's disease-related memory loss, reduced long-term potentiation, enhanced long-term depression, altered adult hippocampal neurogenesis, and amyloid beta-related disruption of plasticity are described. Stress-related mechanisms involving glucocorticoids and excitatory amino acids are also linked to hippocampal atrophy and memory deficits.
Conditions associated with memory impairment in the grounding include dementia, craniocerebral trauma, encephalitis, alcoholism, and schizophrenia. High stress levels are also described as impairing memory function, and traumatic stressors are linked to long-term hippocampal and memory effects.
The supplied grounding does not provide a general treatment standard for memory disorders as a category. It only indicates that therapy is a covered literature aspect and that Alzheimer's-related memory impairment is discussed in relation to emerging therapeutic strategies, without specifying a standard modality or drug class.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.